Cresco Labs Inc. (CRLBF) Asset Writedowns and Impairment (2020 - 2026)

Cresco Labs (CRLBF) has reported Asset Writedowns and Impairment for 5 consecutive years, with $877000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Asset Writedowns and Impairment fell 90.49% year-over-year to $877000.0; the trailing twelve-month figure through Jun 2026 stood at $97.1 million (up 944.84% YoY), and the FY2025 full-year result was $105.1 million, up 4430.22% from the prior year.
• Asset Writedowns and Impairment improved to $877000.0 in Q2 2026 per CRLBF's latest filing, from $342000.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $129.5 million in Q3 2023 and bottomed at $24000.0 in Q4 2023.
• Historically, Asset Writedowns and Impairment has averaged $29.5 million across 3 years, with a median of $1.6 million in 2025.
• The widest YoY moves for Asset Writedowns and Impairment: up 776.92% in 2026, down 90.49% in 2026.
• Over 3 years, Asset Writedowns and Impairment stood at $24000.0 in 2023, then jumped by 389362.5% to $93.5 million in 2025, then sank by 99.06% to $877000.0 in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $877000.0, $342000.0, and $93.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.